Venetoclax-based therapy in relapsed/refractory multiple myeloma harboring t(11;14): report of one case and review of literature / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 166-170, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-882258
ABSTRACT
Objective:
To explore the effect of venetoclax-based therapy on relapsed/refractory multiple myeloma (MM) patients harboring t(11;14).Methods:
The data of a relapsed/refractory MM patient harboring t(11;14) treated with venetoclax-based regimen admitted to Shanghai Changzheng Hospital in June 2019 was retrospectively analyzed and the literatures were reviewed.Results:
The relapsed/refractory MM patient harboring t(11;14) had progression of disease after 3 lines of therapies, and then was treated with the selective bcl-2 inhibitor venetoclax combined with daratumumab and dexamethasone. As a result, the patient achieved partial remission and better hemogram recovery. The Eastern Cooperative Oncology Group (ECOG) score of physical status decreased from 3 to 1, and the quality of life was improved significantly.Conclusions:
The relapsed/refractory MM patients harboring t(11;14) could benefit from venetoclax-based therapy. In the future, the safety, sensitivity and other performances of venetoclax in the treatment of MM should be further explored.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS